

Top Line Performance Metrics

- Plan Cost PMPM increased \$7.12 (+11.3%) to \$70.37, primarily driven by the Utilization Trend Component
- Specialty Plan Cost PMPM increased \$4.86 (+18.3%) to \$31.45, primarily driven by the Specialty Utilization Trend Component
- Generic Fill Rate (GFR) increased 0.8 percentage points to 88.6%

RMD			
Description	7-16 - 6-17	7-15 - 6-16	Change
Avg Subscribers per Month	28,449	29,375	-3.2%
Avg Members per Month	61,937	64,525	-4.0%
Number of Unique Patients	46,570	48,734	-4.4%
Pct Members Utilizing Benefit	75.2%	75.5%	-0.3
Total Plan Cost	\$52,301,463	\$48,969,966	6.8%
Total Days	20,253,427	19,951,958	1.5%
Total Adjusted Rxs	778,861	772,773	0.8%
Average Member Age	35.5	35.3	0.6%
Plan Cost PMPM	\$70.37	\$63.24	11.3%
Plan Cost/Day	\$2.58	\$2.45	5.2%
Plan Cost per Adjusted Rx	\$67.15	\$63.37	6.0%
Nbr Adjusted Rxs PMPM	1.05	1.00	5.0%
Generic Fill Rate	88.6%	87.8%	0.8
Home Delivery Utilization	44.4%	34.6%	9.9
Member Cost %	12.9%	11.9%	1.0
Specialty Percent of Plan Cost	44.7%	42.0%	2.6
Specialty Plan Cost PMPM	\$31.45	\$26.59	18.3%
Formulary Compliance Rate	98.8%	98.6%	0.2



Key Statistics: Specialty Detailed

- Specialty Plan Cost PMPM increased \$4.86 (+18.3%) to \$31.45, primarily driven by the Specialty Utilization Trend Component
- You have 822 unique specialty patients, an increase of 7 specialty patients.

Description	RMD					
	Non-Specialty			Specialty		
	7-16 - 6-17	7-15 - 6-16	Change	7-16 - 6-17	7-15 - 6-16	Change
Avg Subscribers per Month	28,449	29,375	-3.2%	28,449	29,375	-3.2%
Avg Members per Month	61,937	64,525	-4.0%	61,937	64,525	-4.0%
Number of Unique Patients	46,540	48,662	-4.4%	822	815	0.9%
Pct Members Utilizing Benefit	75.1%	75.4%	-0.3	1.3%	1.3%	0.1
Total Plan Cost	\$28,925,504	\$28,378,882	1.9%	\$23,375,959	\$20,591,084	13.5%
Percent of Total Plan Cost	55.3%	58.0%	-2.6	44.7%	42.0%	2.6
Total Days	20,137,589	19,851,735	1.4%	115,838	100,223	15.6%
Total Adjusted Rx	774,545	769,037	0.7%	4,316	3,736	15.5%
Percent of Total Adjusted Rx	99.45%	99.52%	-0.1	0.55%	0.48%	0.1
Plan Cost PMPM	\$38.92	\$36.65	6.2%	\$31.45	\$26.59	18.3%
Plan Cost/Day	\$1.44	\$1.43	0.5%	\$201.80	\$205.45	-1.8%
Plan Cost per Adjusted Rx	\$37.35	\$36.90	1.2%	\$5,416.12	\$5,511.53	-1.7%
Nbr Adjusted Rx PMPM	1.04	0.99	4.9%	0.006	0.005	20.4%
Generic Fill Rate	89.0%	88.1%	0.9	13.7%	16.2%	-2.5
Member Cost %	20.4%	18.3%	2.1	1.5%	1.2%	0.3



Trend Components: Increases Specialty

By Indication

- Majority due to increased Utilization

Overall Specialty Trend	
Current Plan Cost PMPM	\$31.45
Previous Plan Cost PMPM	\$26.59
% Change Plan Cost PMPM	18.3%

Total Trend %							
Trend Driver Rank	Indication	Curr Plan Cost Rank	Curr Plan Cost PMPM	Prev Plan Cost PMPM	Plan Cost PMPM % Change	Plan Cost PMPM \$ Change	Primary Trend Driver (+)
1	INFLAMMATORY CONDITIONS	1	\$10.02	\$7.10	41.2%	\$2.93	Utilization
2	MULTIPLE SCLEROSIS	2	\$5.80	\$4.40	31.9%	\$1.40	Utilization
3	CANCER	3	\$3.85	\$3.32	16.0%	\$0.53	Inflation/ Mix
4	IMMUNE DEFICIENCY	6	\$1.57	\$1.05	49.6%	\$0.52	Utilization
5	SEIZURES	9	\$0.56	\$0.23	141.3%	\$0.33	Utilization
6	HEMOPHILIA	5	\$2.93	\$2.72	7.5%	\$0.20	Inflation/ Mix
7	ASTHMA	10	\$0.30	\$0.14	108.7%	\$0.15	Utilization
8	OSTEOPOROSIS	14	\$0.18	\$0.05	295.9%	\$0.14	Utilization
9	SLEEP DISORDERS	17	\$0.07		0.0%	\$0.07	Newly Utilized
10	INFERTILITY	16	\$0.12	\$0.05	121.0%	\$0.06	Inflation/ Mix



Trend Components: Decreases Specialty

By Indication

- Decreases in trend vary by specialty drug class and may be due to a number of factors, including a change in demographics, new dispensing guidelines or changes in benefit design

Overall Specialty Trend	
Current Plan Cost PMPM	\$31.45
Previous Plan Cost PMPM	\$26.59
% Change Plan Cost PMPM	18.3%

Total Trend %

Trend Driver Rank	Indication	Curr Plan Cost Rank	Curr Plan Cost PMPM	Prev Plan Cost PMPM	Plan Cost PMPM % Change	Plan Cost PMPM \$ Change	Primary Trend Driver (-)
1	HEPATITIS C	4	\$3.33	\$4.45	-25.1%	-\$1.12	Utilization
2	PULMONARY HYPERTENSION	7	\$0.84	\$1.18	-28.4%	-\$0.33	Utilization
3	ALPHA 1 DEFICIENCY	8	\$0.64	\$0.78	-18.5%	-\$0.14	Utilization
4	ENDOCRINE DISORDERS	13	\$0.24	\$0.30	-20.1%	-\$0.06	Utilization
5	GROWTH DEFICIENCY	11	\$0.30	\$0.33	-10.5%	-\$0.03	Inflation/ Mix
6	CYSTIC FIBROSIS	15	\$0.12	\$0.13	-10.9%	-\$0.01	Utilization



Top 10 Indications

- The largest financially impactful change was in Inflammatory Conditions driving \$2.0M in cost from a 39.1% increase in PMPM
- The highest trend is in Immune Deficiency at 49.6%, contributing an additional \$0.52 to PMPM

REPRESENT
64.9%
OF YOUR TOTAL
PLAN COST

Top Indications by Plan Cost													
7-16 - 6-17							7-15 - 6-16					%	
Rank	Indication	Adjusted		Generic Plan Cost	Fill Rate	PMPM	Rank	Adjusted		Generic Plan Cost	Fill Rate	PMPM	% Change
		Rxs	Patients					Rxs	Patients				
1	INFLAMMATORY CONDITIONS	3,164	418	\$7,889,527	28.5%	\$10.61	2	2,905	421	\$7.63	31.7%	\$7.63	39.1%
2	DIABETES	57,932	4,376	\$7,671,113	59.4%	\$10.32	1	54,473	4,428	\$8.53	60.5%	\$8.53	21.0%
3	MULTIPLE SCLEROSIS	718	78	\$4,310,488	6.3%	\$5.80	4	613	86	\$4.40	5.7%	\$4.40	31.9%
4	CANCER	3,980	548	\$3,212,744	93.2%	\$4.32	5	3,693	543	\$3.46	93.2%	\$3.46	25.0%
5	HEPATITIS C	132	36	\$2,477,048	25.0%	\$3.33	3	218	57	\$4.45	33.9%	\$4.45	-25.1%
6	HEMOPHILIA	54	9	\$2,174,854	0.0%	\$2.93	6	56	7	\$2.72	0.0%	\$2.72	7.5%
7	HIV	1,352	110	\$1,882,478	10.3%	\$2.53	8	1,318	90	\$1.97	17.2%	\$1.97	28.5%
8	ASTHMA	25,471	6,676	\$1,688,892	43.9%	\$2.27	9	25,969	7,519	\$1.95	42.8%	\$1.95	16.4%
9	PAIN/INFLAMMATION	66,256	16,220	\$1,446,321	98.0%	\$1.95	7	67,064	16,928	\$2.13	97.8%	\$2.13	-8.4%
10	IMMUNE DEFICIENCY	128	15	\$1,165,482	0.0%	\$1.57	14	81	9	\$1.05	0.0%	\$1.05	49.6%
	Total Top 10:	159,187		\$33,918,946	72.5%	\$45.64	156,390			\$38.29	73.1%	\$38.29	19.2%
	Differences Between Periods:	2,797		\$4,270,330	-0.6%	\$7.35							



Top 25 Drugs

- Represent 37.5% of your total Plan Cost and comprise 11 indications
- 17 of your top 25 are specialty drugs, making up 75.5% of your Top 25 spend

Top Drugs by Plan Cost												
7-16 - 6-17							7-15 - 6-16			% Change		
Rank	Brand Name	Indication	Adj. Rxs	Pts.	Plan Cost	Plan Cost PMPM	Rank	Adj. Rxs	Pts.	Plan Cost PMPM	Plan Cost PMPM	% Change
1	HUMIRA PEN*	INFLAMMATORY CONDITIONS	710	108	\$3,227,313	\$4.34	1	629	94	\$3.01	\$4.34	44.3%
2	ENBREL*	INFLAMMATORY CONDITIONS	430	62	\$1,803,483	\$2.43	3	436	74	\$2.06	\$2.43	17.9%
3	HARVONI*	HEPATITIS C	38	16	\$1,203,228	\$1.62	8	23	10	\$0.94	\$1.62	72.5%
4	COPAXONE*	MULTIPLE SCLEROSIS	199	27	\$1,081,451	\$1.46	6	182	29	\$1.21	\$1.46	20.3%
5	HELIXATE FS*	HEMOPHILIA	25	1	\$977,166	\$1.31	4	25	1	\$1.31	\$1.31	0.1%
6	GILENYA*	MULTIPLE SCLEROSIS	135	15	\$919,147	\$1.24	9	116	14	\$0.91	\$1.24	36.1%
7	HUMALOG	DIABETES	1,454	210	\$758,947	\$1.02	11	1,335	225	\$0.78	\$1.02	30.5%
8	TRULICITY	DIABETES	1,414	209	\$756,840	\$1.02	30	688	115	\$0.42	\$1.02	142.7%
9	LANTUS SOLOSTAR	DIABETES	2,267	363	\$739,458	\$0.99	7	2,205	395	\$0.98	\$0.99	1.6%
10	HUMALOG KWIKPEN U-100	DIABETES	1,257	229	\$688,569	\$0.93	10	1,352	267	\$0.83	\$0.93	11.7%
11	SPRYCEL*	CANCER	52	6	\$641,903	\$0.86	13	53	6	\$0.72	\$0.86	19.7%
12	TECFIDERA*	MULTIPLE SCLEROSIS	93	12	\$626,088	\$0.84	16	81	15	\$0.63	\$0.84	34.4%
13	HUMATE-P*	HEMOPHILIA	10	2	\$624,660	\$0.84	5	22	1	\$1.30	\$0.84	-35.3%
14	AUBAGIO*	MULTIPLE SCLEROSIS	99	12	\$593,138	\$0.80	27	69	14	\$0.50	\$0.80	59.2%
15	IMATINIB MESYLATE*	CANCER	65	6	\$563,461	\$0.76	44	23	5	\$0.27	\$0.76	178.3%
16	LEVEMIR FLEXTOUCH	DIABETES	1,214	203	\$554,212	\$0.75	12	1,325	236	\$0.76	\$0.75	-1.4%
17	JANUVIA	DIABETES	1,765	283	\$513,347	\$0.69	20	1,600	280	\$0.58	\$0.69	18.9%
18	HUMIRA*	INFLAMMATORY CONDITIONS	114	16	\$500,703	\$0.67	15	140	23	\$0.64	\$0.67	5.0%
19	EPCLUSA*	HEPATITIS C	19	7	\$470,054	\$0.63						
20	SYMBICORT	ASTHMA	2,070	472	\$430,060	\$0.58	21	2,190	533	\$0.58	\$0.58	0.4%
21	SABRIL*	SEIZURES	25	2	\$414,786	\$0.56	58	12	1	\$0.23	\$0.56	141.3%
22	VIEKIRA PAK*	HEPATITIS C	15	7	\$410,337	\$0.55	2	70	34	\$2.53	\$0.55	-78.1%
23	GAMMAGARD LIQUID*	IMMUNE DEFICIENCY	23	2	\$397,317	\$0.53	718	1	1	\$0.01	\$0.53	7367.6%
24	ARALAST NP*	ALPHA 1 DEFICIENCY	27	2	\$365,090	\$0.49	46	13	1	\$0.27	\$0.49	84.7%
25	TRUVADA	HIV	305	50	\$363,821	\$0.49	29	284	41	\$0.44	\$0.49	11.1%
		Total Top 25:	13,825		\$19,624,580	\$26.40		12,874		\$21.90	\$26.40	20.6%
		Differences Between Periods:	951		\$2,670,502	\$4.51						

*Specialty Drugs



Top 10 Specialty Indications

- The largest financially impactful change in Specialty was in Inflammatory Conditions driving \$2.0M in cost from a 41.2% increase in PMPM
- The highest trend is in Seizures at 141.3%, contributing an additional \$0.33 to PMPM

Top Specialty Indications by Plan Cost											
7-16 - 6-17						7-15 - 6-16					%
Overall Rank	Indication	Adjusted		Plan Cost		Overall Rank	Adjusted		Plan Cost		Plan Cost PMPM
		Rxs	Patients	Plan Cost	PMPM		Rxs	Patients	Plan Cost	PMPM	
1	INFLAMMATORY CONDITIONS	1,738	229	\$7,450,234	\$10.02	2	1,501	220	\$5,496,258	\$7.10	41.2%
3	MULTIPLE SCLEROSIS	718	78	\$4,310,488	\$5.80	4	613	86	\$3,404,490	\$4.40	31.9%
4	CANCER	371	63	\$2,864,037	\$3.85	5	360	64	\$2,571,091	\$3.32	16.0%
5	HEPATITIS C	132	36	\$2,477,048	\$3.33	3	218	57	\$3,447,103	\$4.45	-25.1%
6	HEMOPHILIA	54	9	\$2,174,854	\$2.93	6	56	7	\$2,108,188	\$2.72	7.5%
10	IMMUNE DEFICIENCY	128	15	\$1,165,482	\$1.57	14	81	9	\$811,591	\$1.05	49.6%
20	PULMONARY HYPERTENSION	103	9	\$627,125	\$0.84	13	136	12	\$912,626	\$1.18	-28.4%
27	ALPHA 1 DEFICIENCY	38	4	\$472,157	\$0.64	22	53	4	\$603,494	\$0.78	-18.5%
11	SEIZURES	25	2	\$414,786	\$0.56	17	12	1	\$179,064	\$0.23	141.3%
8	ASTHMA	92	14	\$221,101	\$0.30	9	51	8	\$110,377	\$0.14	108.7%
Total Top 10:		3,399		\$22,177,310	\$29.84	3,081		\$19,644,282	\$25.37	17.6%	
Differences Between Periods:		318		\$2,533,027	\$4.47						



Top 25 Specialty Drugs

- Represent 32.5% of your total Plan Cost and comprise 8 indications

Top Specialty Drugs by Plan Cost														
7-16 - 6-17									7-15 - 6-16					% Change
Overall Rank	Brand Name	Indication	Adj. Rxs	Pts.	Plan Cost	Plan Cost / Adj. Rx	Plan Cost PMPM	Overall Rank	Adj. Rxs	Pts.	Plan Cost / Adj. Rx	Plan Cost PMPM	Plan Cost PMPM	% Change
1	HUMIRA PEN	INFLAMMATORY CONDITIONS	710	108	\$3,227,313	\$4,546	\$4.34	1	629	94	\$3,704	\$3.01	\$3.01	44.3%
2	ENBREL	INFLAMMATORY CONDITIONS	430	62	\$1,803,483	\$4,194	\$2.43	3	436	74	\$3,656	\$2.06	\$2.06	17.9%
3	HARVONI	HEPATITIS C	38	16	\$1,203,228	\$31,664	\$1.62	8	23	10	\$31,603	\$0.94	\$0.94	72.5%
4	COPAXONE	MULTIPLE SCLEROSIS	199	27	\$1,081,451	\$5,434	\$1.46	6	182	29	\$5,145	\$1.21	\$1.21	20.3%
5	HELIXATE FS	HEMOPHILIA	25	1	\$977,166	\$39,087	\$1.31	4	25	1	\$40,681	\$1.31	\$1.31	0.1%
6	GILENYA	MULTIPLE SCLEROSIS	135	15	\$919,147	\$6,808	\$1.24	9	116	14	\$6,067	\$0.91	\$0.91	36.1%
11	SPRYCEL	CANCER	52	6	\$641,903	\$12,344	\$0.86	13	53	6	\$10,539	\$0.72	\$0.72	19.7%
12	TECFIDERA	MULTIPLE SCLEROSIS	93	12	\$626,088	\$6,732	\$0.84	16	81	15	\$5,992	\$0.63	\$0.63	34.4%
13	HUMATE-P	HEMOPHILIA	10	2	\$624,660	\$62,466	\$0.84	5	22	1	\$45,749	\$1.30	\$1.30	-35.3%
14	AUBAGIO	MULTIPLE SCLEROSIS	99	12	\$593,138	\$5,991	\$0.80	27	69	14	\$5,625	\$0.50	\$0.50	59.2%
15	IMATINIB MESYLATE	CANCER	65	6	\$563,461	\$8,669	\$0.76	44	23	5	\$9,170	\$0.27	\$0.27	178.3%
18	HUMIRA	INFLAMMATORY CONDITIONS	114	16	\$500,703	\$4,392	\$0.67	15	140	23	\$3,548	\$0.64	\$0.64	5.0%
19	EPCLUSA	HEPATITIS C	19	7	\$470,054	\$24,740	\$0.63							
21	SABRIL	SEIZURES	25	2	\$414,786	\$16,591	\$0.56	58	12	1	\$14,922	\$0.23	\$0.23	141.3%
22	VIEKIRA PAK	HEPATITIS C	15	7	\$410,337	\$27,356	\$0.55	2	70	34	\$27,936	\$2.53	\$2.53	-78.1%
23	GAMMAGARD LIQUID	IMMUNE DEFICIENCY	23	2	\$397,317	\$17,275	\$0.53	718	1	1	\$5,543	\$0.01	\$0.01	7367.6%
24	ARALAST NP	ALPHA 1 DEFICIENCY	27	2	\$365,090	\$13,522	\$0.49	46	13	1	\$15,839	\$0.27	\$0.27	84.7%
32	KOATE	HEMOPHILIA	4	1	\$292,121	\$73,030	\$0.39							
33	GAMUNEX-C	IMMUNE DEFICIENCY	37	4	\$291,973	\$7,891	\$0.39	161	13	3	\$4,615	\$0.08	\$0.08	407.0%
34	ORENCIA	INFLAMMATORY CONDITIONS	74	12	\$286,211	\$3,868	\$0.39	33	77	11	\$3,480	\$0.35	\$0.35	11.3%
36	REBIF REBIDOSE	MULTIPLE SCLEROSIS	41	5	\$269,856	\$6,582	\$0.36	43	36	5	\$5,882	\$0.27	\$0.27	32.8%
37	AVONEX PEN	MULTIPLE SCLEROSIS	45	5	\$269,098	\$5,980	\$0.36	48	37	4	\$5,343	\$0.26	\$0.26	41.8%
39	BENEFIX	HEMOPHILIA	11	2	\$258,215	\$23,474	\$0.35	153	4	2	\$15,909	\$0.08	\$0.08	322.7%
40	TARCEVA	CANCER	33	4	\$250,647	\$7,595	\$0.34	88	16	5	\$7,061	\$0.15	\$0.15	131.1%
41	REVLIMID	CANCER	22	4	\$244,361	\$11,107	\$0.33	81	12	3	\$10,420	\$0.16	\$0.16	103.6%
		Total Top 25:	2,346		\$16,981,809	\$7,239	\$22.85		2,090		\$6,622	\$17.87	\$17.87	27.8%
		Differences Between Periods:	256		\$3,142,781	\$617	\$4.98							

